Evidence mapPaperPMID 37850093Full record

ArticleFrontiers in endocrinology2023

May Majimbi, Samuel McLenachan, Michael Nesbit, Fred K Chen, Virginie Lam, John Mamo, Ryu Takechi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

May MajimbiCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.
Samuel McLenachanLions Eye Institute Australia, Harry Perkins Institute of Medical Research, Nedlands, WA, Australia.
Michael NesbitCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.
Fred K ChenLions Eye Institute Australia, Harry Perkins Institute of Medical Research, Nedlands, WA, Australia.
Virginie LamCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.
John MamoCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.
Ryu TakechiCurtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia.
Curtin University · AUHarry Perkins Institute of Medical Research · AULions Eye Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Type 2 diabetes (T2D) is associated with chronic inflammation and neurovascular changes that lead to functional impairment and atrophy in neural-derived tissue. A reduction in retinal thickness is an early indicator of diabetic retinopathy (DR), with progressive loss of neuroglia corresponding to DR severity. The brain undergoes similar pathophysiological events as the retina, which contribute to T2D-related cognitive decline. Methods: This study explored the relationship between retinal thinning and cognitive decline in the LepR Results: At 28 weeks, mice exhibited retinal thinning in the ganglion cell complex and inner nuclear layer, concomitant with diabetic insulin resistance, memory deficits, increased expression of inflammation markers and cerebrovascular leakage. Interestingly, alterations in retinal thickness at both experimental timepoints were correlated with cognitive decline and elevated immune response in the brain and retina. Discussion: These results suggest that changes in retinal thickness quantified with

Indexed as

Cognitive DysfunctionDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diabetic RetinopathyAnimalsBlood-Brain BarrierInflammationMiceNeuroinflammatory DiseasesRetinablood brain barriercorrelationdiabetic cognitive declineneuroinflammationoxidative stressretina neurodegeneration

Identifiers

PMID37850093
PMCPMC10577437
OpenAlexW4387308030

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.